Targeting L-arginine-nitric oxide-cGMP pathway in pulmonary arterial hypertension

Documenti analoghi

• Targeting L-arginine-nitric oxide-cGMP pathway in pulmonary arterial hypertension
  di: Haiyang Tang, et al.
  Pubblicazione: (2017-09-01)
• Is p38 MAPK a Dark Force in Right Ventricular Hypertrophy and Failure in Pulmonary Arterial Hypertension?
  di: Vanderpool, Rebecca R., et al.
  Pubblicazione: (2017)
• Prolonged treatment of porcine pulmonary artery with nitric oxide decreases cGMP sensitivity and cGMP-dependent protein kinase specific activity
  di: Perkins, William J., et al.
  Pubblicazione: (2009)
• cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action
  di: Francis, Sharron H., et al.
  Pubblicazione: (2010)
• Thrombin Has Biphasic Effects on the Nitric Oxide-cGMP Pathway in Endothelial Cells and Contributes to Experimental Pulmonary Hypertension
  di: Nickel, Katrin F., et al.
  Pubblicazione: (2013)